Objective: To assess the effect of metformin administration on thyroid function in overweight women with polycystic ovarian syndrome (PCOS). Methods: Twenty-seven overweight women with PCOS and hypothyroidism were selected. Fifteen patients (group I) were treated with metformin 1500 mg/day for 6 months and 12 patients (group II) with placebo. Serum thyrotropin (TSH), free T3 and free T4 were measured at baseline and 6 months after the beginning of the study. Results: A significant decrease (p<0.001) in TSH levels was observed in group I but not in group II subjects after 6 months of metformin treatment. No significant change in free T3 and free T4 was observed throughout the study in any group. Conclusion: In obese PCOS patients with primary hypothyroidism, metformin results in a significant fall and sometimes normalisation of TSH, without causing any reciprocal changes in other thyroid function parameters.
Introduction
Polycystic ovarian syndrome (PCOS) is a common endocrinopathy occurring in five to seven per cent of women of reproductive age and primary hypothyroidism is also very prevalent in women and occurs more commonly in PCOS. 1 Metformin has been used for the treatment of type 2 diabetes and PCOS for many years. Recently there have been some reports that metformin is able to influence thyroid function tests, mainly by a decrease in serum levels of thyrotropin (TSH). 2 We evaluate the interplay between metformin and thyroid tests by following thyroid hormone levels in overweight PCOS patients with hypothyroidism after treatment with metformin or placebo.
Patients and methods
This study performed in 27 overweight women with PCOS and primary hypothyroidism. PCOS was diagnosed in accordance with the Rotterdam consensus diagnostic criteria. Hypothyroidism in all patients was subclinical and was diagnosed for the first time. Fifteen patients (group I) were treated with metformin 1500 mg/day for 6 months and 12 patients (group II) with placebo. The patients did not receive any other medications for treatment of PCOS. Serum TSH, free T4 (FT 4 ) and free T3 (FT 3 ) were measured once at baseline and 6 months after the beginning of the subclinical hypothyroidism. 3 Serum FT4 and FT3 levels did not change significantly during study in any group (Table 1 ).
Discussion
These data show for the first time that metformin administration in overweight PCOS patients with primary subclinical hypothyroidism results in a significant fall in TSH levels. This is an important finding clinically, because hypothyroidism occurs in more than 10% of PCOS patients 1 and metformin is a common prescription in them. There are several possible explanations for the TSH-reducing effect of metformin but they are speculative at the present time. A subtle increase in the gastrointestinal absorption of levothyroxin is the first possible mechanism, but a reduction in thyroid hormone levels was not reciprocal with TSH in patients with hypothyroidism treated with levothyroxin in initial case reports by Vigersky et al. 4 This finding was also shown in another study by Cappelli et al. He also ruled out any influence of changes in body weight associated with metformin therapy on TSH levels. 2 Our study also confirms these findings.
Enhancement of inhibitory feedback of thyroid hormones on TSH secretion is another mechanism suggested by Cappelli et al. 2 Induced constituent activation of the TSH receptor and increased dopaminergic tone has also had been suggested by Vigersky et al. 4 Previous studies have suggested that there is a disruption of the neuroendocrine mechanisms in women with PCOS, mainly due to a deficiency in hypothalamic dopamine. 5 Metformin administration improves endogenous hypothalamic dopaminergic tone, simultaneously with decreasing the insulin resistance in obese PCOS patients. 6 The possibility that metformin administration decreases TSH levels by increasing dopamine in the hypothalamus may be the best explanation but needs to be fully elucidated by further studies.
The main limitation of our study was the small number of patients. However, a significant decrease in TSH levels was observed in our patients.
Conclusion
In overweight PCOS patients with primary hypothyroidism, treatment with metformin resulted in a significant fall in TSH and in some cases improvement of hypothyroidism. We can begin treatment of obese PCOS patients with subclinical hypothyroidism with metformin and reevaluate their thyroid function after six months.
